SPRINGER NATURE

Corresponding Author Name: Ao Mo
Manuscript Number: CDDIS-25-2488

Reporting Summary

Springer Nature wishes to improve the reproducibility of the work that we publish. This checklist is used to ensure good reporting standards and to improve the reproducibility. Please respond completely to all questions relevant to your manuscript. For more information, please read the journal's Guide to Authors.

☑ **Check here to confirm that the following information is available in the Material & Methods section:**

- **The exact sample size (*n*)** for each experimental group/condition, given as a number, not a range
- **A description of the sample collection** allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, culture, etc.)
- **A statement of how many times the experiment shown was replicated in the laboratory**
- **Definitions of statistical methods and measures**: For small sample sizes (n<5) descriptive statistics are not appropriate, instead plot individual data points
    - Very common tests, such as *t*-test, simple χ^2 tests, Wilcoxon and Mann-Whitney tests, can be unambiguously identified by name only, but more complex techniques should be described in the methods section
    - Are tests one-sided or two-sided?
    - Are there adjustments for multiple comparisons?
    - **Statistical test results**, e.g., ***P* values**
    - Definition of **'center values'** as **median or mean**;
    - Definition of **error bars as s.d. or s.e.m. or c.i.**

Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents and animal models. Below, provide the page number or section and paragraph number.

Statistics and general methods	**Reported in section/paragraph or page #**
1. How was the sample size chosen to ensure adequate power to detect a pre-specified effect size? (Give section/paragraph or page #)	Statistical Analysis section in Materials and Methods
For animal studies, include a statement about sample size estimate even if no statistical methods were used.	Sample sizes for animal studies were determined based on preliminary data indicating that n=4 per group provides 80% power to detect 30% difference in tumor volume (α=0.05) using G*Power.
2. Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria pre-established? (Give section/paragraph or page #)	Clinical Sample Collection and Statistical Analysis section in Materials and Methods
3. If a method of randomization was used to determine how samples/animals were allocated to experimental groups and processed, describe it. (Give section/paragraph or page #)	Animal Xenograft Models section in Materials and Methods
For animal studies, include a statement about randomization even if no randomization was used.	Mice were randomly assigned to treatment groups using a r andom number table by an independent researcher.

4. If the investigator was blinded to the group allocation during the experiment and/or when assessing the outcome, state the extent of blinding. (Give section/paragraph or page #)	Animal Xenograft Models section in Materials and Methods
For animal studies, include a statement about blinding even if no blinding was done.	Tumor measurements and histological scoring were perfor med by investigators blinded to group allocation.
5. For every figure, are statistical tests justified as appropriate?	Normally distributed data were analyzed by parametric test s (t-test/ANOVA); non-normal data used Mann-Whitney/Kr uskal-Wallis tests
Do the data meet the assumptions of the tests (e.g., normal distribution)?	Data normality was confirmed by Shapiro-Wilk test (P>0.05) . Non-normal data were log-transformed or analyzed by non -parametric tests.
Is there an estimate of variation within each group of data?	Error bars represent standard deviation (SD).
Is the variance similar between the groups that are being statistically compared? (Give section/paragraph or page #)	Statistical Analysis section in Materials and Methods

Reagents

	Reported in section/paragraph or page #
6. Report the source of antibodies (vendor and catalog number)	(81196-1-RR), FTH1 (11682-1-AP), GPX4 (67763-1-Ig), ATG5 (66744-1-Ig), p62 (66184-1-Ig), and LC3 (14600-1-AP), all pri marily obtained from Proteintech (Wuhan, China).
7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination	HEK293T cells, normal human colon epithelial mucosal cells (NCM460), and colorectal cancer cell lines LoVo, RKO, SW48 0, and HT115, all procured from the Shanghai Institute of Lif e Sciences (Shanghai, China). Cell lines were authenticated by STR profiling and tested mycoplasma-negative.

Animal Models

	Reported in section/paragraph or page #
8. Report species, strain, sex and age of animals	Species: BALB/c nude mice; Strain: N/A; Sex: Male; Age: 6 – 8 weeks
9. For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.	Approved by the Institutional Animal Care Committee of Fir st Affiliated Hospital of USTC.

10. We recommend consulting the ARRIVE guidelines (*PLoS Biol.* **8**(6), e1000412,2010) to ensure that other relevant aspects of animal studies are adequately reported.

Human subjects

	Reported in section/paragraph or page #
11. Identify the committee(s) approving the study protocol.	The storage, analysis, and disposal of these samples were conducted in compliance with the guidelines approved by the Clinical Medical Ethics Committee of First Affiliated Hospital of University of Science and Technology of China.
12. Include a statement confirming that informed consent was obtained from all subjects.	Written informed consent was obtained from all participants
13. For publication of patient photos, include a statement confirming that consent to publish was obtained.	N/A
14. Report the clinical trial registration number (at ClinicalTrials.gov or equivalent).	N/A

15. For phase II and III randomized controlled trials, please refer to the CONSORT statement and submit the CONSORT checklist with your submission.

16. For tumor marker prognostic studies, we recommend that you follow the REMARK reporting guidelines.

Data deposition

	Reported in section/paragraph or page #
17. Provide accession codes for deposited data. Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Microarray data	Data available upon request from corresponding authors.

Deposition is strongly recommended for many other datasets for which structured public repositories exist; more details on our data policy are available in the Guide to Authors. We encourage the provision of other source data in supplementary information or in unstructured repositories such as Figshare and Dryad. We encourage publication of Data Descriptors (see Scientific Data) to maximize data reuse.

18. If computer code was used to generate results that are central to the paper's conclusions, include a statement in the Methods section under "**Code availability"** to indicate whether and how the code can be accessed. Include version information as necessary and any restrictions on availability.	N/A